論文（2011）

著書

  1. 木村晋也：第５章１）ABL チロシンキナーゼ阻害薬による治療の現状と今後の展望．秒進分歩す る癌研究の最前線．実験医学増刊，羊土社．東京 2011．
  2. 木村晋也：CML 治療の現状．白血病治療におけるダサチニブ（スプリセル）のすべて，メディカ ルレビュー．東京    2011．

原著論文

  1. Fukushima N, Itamura H, Urata C, Tanaka M, Hisatomi T, Kubota Y, Sueoka E, Kimura S: Clinical Presenta- tion and Outcome in Patients of over 75 Years Old with Malignant Lymphoma-Clinical Presentation and Out- come in Elderly Lymphoma Patients. Int J Clin Med 2(3): 246-253, 2011.
  2. Hisatomi T, Sueoka-Aragane N, Sato A, Tomimasu R, Ide M, Kunimasa A, Okamoto K, Kimura S, Sueoka E:NK 314 potentiates anti-tumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIa and DNA-dependent protein kinase. Blood 117(13): 3575-84, 2011.
  3. Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T: Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp 90 in mantle cell lym- phoma. Brit J Cancer 104(1): 91-100, 2011.
  4. Kawatani M, Takayama H, Muroi M, Kimura S, Maekawa T. Osada H.1:Identification of a small molecule inhibitor of DNA topoisomerase II by proteomic profiling. Chem Biol 18(6): 743-5, 2011.
  5. Nagao R, Ashihara E, Kimura S, Strovel JW, Yao H, Takeuchi M, Tanaka R, Hayashi Y, Hirai H, Padia J, Strand K, Maekawa T: Growth inhibition of imatinib-resistant CML cells with the T 315 I mutation and hy- poxia adaptation by AV 65,a novel Wnt/β-catenin signaling inhibitor. Cancer Lett 312(1): 91-100, 2011.
  6. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T,Hirai M, Sueoka E, Kimura S: A non-invasive system for monitoring resistance to EGFR tyrosine kinase in- hibitors with plasma DNA. J Thorac Oncol 6(10): 1639-48, 2011.
  7. Sato T, Ichinohe T, Kanda J, Yamashita K, Kondo T, Ishikawa T, Uchiyama T, Takaori-Kondo A: Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. Int J Hematol 93(4): 532-541, 2011.
  8. Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao H, Nagao R, Tanaka R, Yokota A, Takeuchi M,Hirai H, Kimura S, Hirashima M, Yoshimura N, Maekawa T: Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol 41(1): 67-75, 2011.
  9. Takeuchi M, Ashihara E, Yamazaki Y, Kimura S, Nakagawa Y, Tanaka R, Yao H, Nagao R, Hayashi Y, Hirai H,Maekawa T: Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cencer Sci 102(3): 591-6, 2011.
  10. Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H, Itoh K, Nishiwaki K, Suzuki K, Nagao R, Yao H, Hayashi Y, Satake S, Hirai H, Sawada K, Ottmann OG, Melo JV, Maekawa T: Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett 312: 228-234, 2011.
  11. Tauchi T, Okabe S, Kimura S, Maekawa T, Ohyashiki K: Combined effects of novel heat shock protein 90 inhibitor NVP-AUY 922 and nilotinib in a random mutagenesis screen. Oncogene 30(24): 2789-97, 2011.
  12. Urata C, Yoshimura M, Itamura H, Hisatomi T, Kubota Y, Fukushima N, Sueoka E, Kimura S: Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin. Int J Hematol 94(2): 216-7, 2011.
  13. Ureshino N, Sueoka-Aragane N, Nakamura T, Sato A, Komiya K, Iwanaga K, Mitsuoka M, Takeda Y, Hayashi S, Sueoka E, Kimura S: Fully Integrated, Automated and Rapid Detection System for KRAS Mutations. Oncol Rep 26(3): 609-13, 2011.
  14. Yamaguchi M, Kwong Y, K Kim, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R : Phase II study of SMILE chemo- therapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol, 29: 4410-6, 2011.
  15. Yamamichi J, Ojima T, Yurugi K, Iida M, Imamura T, Ashihara E, Kimura S*, Maekawa T: Single-step, labelfree quantification of antibody in human serum for clinical applications based on localized surface plasmon resonance. Nanomedicine 7(6): 889-895, 2011.

総説

  1. 福島伯泰：悪性リンパ腫における最新の分子標的療法．細胞  43(4)139-142,2011．
  2. 福島伯泰：リツキシマブ治療と B 型肝炎ウイルス再活性化：現状と対策．血液内科  62(5)557-562,2011．
  3. 福島伯泰，宮原正晴，佐野雅之：カラーグラフィック・私のこの一枚(80)Blastic plasmacytoid den- dric cell neoplasm．血液フロンティア  21(2)171-174,2011．
  4. 久富   崇，末岡榮三朗：新規抗がん剤 NK314による ATL の治療．血液内科  63(2):224‐231,2011．
  5. 一戸辰夫，木村晋也：イマチニブ耐性 BCR‐ABL．最新医学  66(11):2587‐2593,2011．
  6. 木村晋也：BCR‐ABL 遺伝子変異と薬剤耐性．日本医師会雑誌  140(7):1464,2011．
  7. 木村晋也：イマチニブは止められるのか？．血液内科 63(3):352‐359,2011．
  8. 木村晋也：分子標的薬の基本．細胞  43(4):124‐126,2011．
  9. 木村晋也：グリベック⑧は止められるの？．Medical Practice   28(8):1476,2011．
  10. 木村晋也：慢性骨髄性白血病に対する新規 BCR‐ABL チロシンキナーゼ阻害薬の開発と今後の展望． がんと化学療法 38(5):754‐758,2011．
  11. 木村晋也：Bafetinib.Biotherapy  25(1):589‐596,2011．
  12. 木村晋也：バフェチニブ（INNO‐406）の作用機構と臨床応用．血液内科  62(1):30-36,2011．
  13. 久保田寧，木村晋也：がん幹細胞に対する破骨細胞標的薬剤の役割  ‐ビスフォスフォネート製剤，RANKL 阻害薬‐．最新医学  66(3):381‐386,2011．
  14. 横尾眞子，久保田寧：WORLD REPORT 52 nd American Society of Hematology Annual Meeting and Ex- position. Trends in Hematological Malignancies 3(1), 2011.

最終更新日：2014年10月1日

(C)佐賀大学医学部附属病院血液・呼吸器・腫瘍内科